An official website of the United States government
Home
Name
Lenalidomide
Alternate Names
Revlimid
lenalidomide
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--antiangiogenesis agent
NSC Number
703813
Primary Site
5q- MDS
CLL
MDS
Multiple myeloma
melanoma
Lymphoma
Histology
None
Remarks
May 28, 2019: FDA approved lenalidomide (REVLIMID) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
2/22/2017: FDA approved lenalidomide (Revlimid) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
July 2013 UPDATE: Revlimid received FDA approval for use in the treatment of mantle cell lymphoma (MCL) whose disease has relapsed after two prior therapies, one of which included bortezomib.
FDA approved for MDS 2005, for multiple myeloma 2006, orphan drug status CLL
Thalidomide analog immunomodulatory derivative.
February 20, 2015 update: FDA approved revlimid given in combination with dexamethasone as first course treatment for newly diagnosed multiple myeloma.
Coding
This drug should be coded
